Business Wire

CA-LATTICEFLOW-AI

12.3.2024 12:31:33 CET | Business Wire | Press release

Share
LatticeFlow AI Appoints Established AI Executives Milena Marinova and Jean-Luc Chatelain to Its Advisory Board

LatticeFlow AI, the leading platform empowering AI teams to build performant, safe, and trustworthy AI solutions, proudly announces the creation of its advisory board and the appointment of two AI luminaries, Milena Marinova and Jean-Luc Chatelain, as founding members.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312894740/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LatticeFlow AI welcomes Milena Marinova and Jean-Luc Chatelain to its advisory board (Photo: Business Wire)

Milena Marinova, brings a wealth of experience and expertise in software development and in the field of AI, ML and GenAI, with over 15 years of launching innovative AI products and solutions globally. Most recently she established the AI Acceleration Studio at Microsoft and currently serves as its Vice President. Milena’s visionary leadership in building intelligent AI systems, emphasizing experimentation and evaluation for human and AI collaboration, aligns with LatticeFlow AI’s mission of delivering trustworthy AI solutions at scale.

“In the era of AI adoption, building responsible AI is paramount to the success of these deployments,” says Milena. “I’m happy to become an advisor to LatticeFlow AI and help advance the vision of its founders and their strong commitment to building tools that ensure AI safety and trust.”

Jean-Luc Chatelain, former CTO of Applied Intelligence at Accenture, is also a seasoned AI expert with a deep understanding of the challenges and opportunities in building and operationalizing mission-critical AI systems for large-scale organizations.

“Trust is the foundation of a successful AI platform,” says Jean-Luc. “I am thrilled to join the LatticeFlow AI’s advisory board and help the company realize its mission of enabling enterprises to build and deploy safe and trustworthy AI systems that unlock business value.”

Milena’s outstanding leadership in pioneering groundbreaking AI solutions, coupled with her profound expertise in machine learning, AI, and deep neural networks, will be invaluable in advancing LatticeFlow AI’s vision of bringing mission-critical AI solutions to market. Similarly, Jean-Luc’s expertise in constructing AI systems for large organizations across the globe, grounded in trust and responsibility, will be pivotal in helping LatticeFlow AI bolster the safety and reliability of its solutions.

“We are honored to welcome Milena and Jean-Luc to our advisory board,” shared LatticeFlow AI’s co-founders Petar Tsankov (CEO) and Pavol Bielik (CTO). “Their collective expertise, aligned with our vision for responsible AI adoption, will be instrumental in guiding our long-term growth strategy in the years to come.”

The creation of LatticeFlow AI’s top-tier AI advisory board follows the expansion of LatticeFlow AI into the US market and the appointment of Tom Ulrich as Senior Vice President and General Manager of LatticeFlow North America.

About LatticeFlow AI

LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312894740/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye